Literature DB >> 24848581

A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease.

David S Goldstein1, Patricia Sullivan1, Courtney Holmes1, Gary W Miller2, Yehonatan Sharabi3, Irwin J Kopin1.   

Abstract

In Parkinson's disease (PD), profound putamen dopamine (DA) depletion reflects denervation and a shift from vesicular sequestration to oxidative deamination of cytoplasmic DA in residual terminals. PD also involves cardiac sympathetic denervation. Whether PD entails myocardial norepinephrine (NE) depletion and a sequestration-deamination shift have been unknown. We measured apical myocardial tissue concentrations of NE, DA, and their neuronal metabolites 3,4-dihydroxyphenylglycol (DHPG), and 3,4-dihydroxyphenylacetic acid (DOPAC) from 23 PD patients and 23 controls and ascertained the extent of myocardial NE depletion in PD. We devised, validated in VMAT2-Lo mice, and applied 5 neurochemical indices of the sequestration-deamination shift-concentration ratios of DOPAC:DA, DA:NE, DHPG:NE, DOPAC:NE, and DHPG:DOPAC-and used a kinetic model to estimate the extent of the vesicular storage defect. The PD group had decreased myocardial NE content (p < 0.0001). The majority of patients (70%) had severe NE depletion (mean 2% of control), and in this subgroup all five indices of a sequestration-deamination shift were increased compared to controls (p < 0.001 for each). Vesicular storage in residual nerves was estimated to be decreased by 84-91% in this subgroup. We conclude that most PD patients have severe myocardial NE depletion, because of both sympathetic denervation and decreased vesicular storage in residual nerves. We found that the majority (70%) of Parkinson's disease (PD) patients have profound (98%) myocardial norepinephrine depletion, because of both cardiac sympathetic denervation and a shift from vesicular sequestration to oxidative deamination of cytoplasmic catecholamines in the residual nerves. This shift may be part of a final common pathogenetic pathway in the loss of catecholaminergic neurons that characterizes PD. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Parkinson's disease; catecholamines; neurochemistry; neurodegenerative mechanisms; sympathetic nervous system

Mesh:

Substances:

Year:  2014        PMID: 24848581      PMCID: PMC4241178          DOI: 10.1111/jnc.12766

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  45 in total

1.  Cardiac sympathetic nerve function in congestive heart failure.

Authors:  G Eisenhofer; P Friberg; B Rundqvist; A A Quyyumi; G Lambert; D M Kaye; I J Kopin; D S Goldstein; M D Esler
Journal:  Circulation       Date:  1996-05-01       Impact factor: 29.690

2.  Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity.

Authors:  Meret Nora Gaugler; Ozgur Genc; Wojciech Bobela; Safa Mohanna; Mustafa Taleb Ardah; Omar Mukhtar El-Agnaf; Marco Cantoni; Jean-Charles Bensadoun; Ralf Schneggenburger; Graham W Knott; Patrick Aebischer; Bernard Laurent Schneider
Journal:  Acta Neuropathol       Date:  2012-02-24       Impact factor: 17.088

Review 3.  Catecholamine metabolism: basic aspects and clinical significance.

Authors:  I J Kopin
Journal:  Pharmacol Rev       Date:  1985-12       Impact factor: 25.468

4.  Cardiac sympathetic denervation in Parkinson disease.

Authors:  D S Goldstein; C Holmes; S T Li; S Bruce; L V Metman; R O Cannon
Journal:  Ann Intern Med       Date:  2000-09-05       Impact factor: 25.391

5.  Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease.

Authors:  Kelly Del Tredici; Christopher H Hawkes; Estifanos Ghebremedhin; Heiko Braak
Journal:  Acta Neuropathol       Date:  2010-03-14       Impact factor: 17.088

6.  Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection.

Authors:  C Holmes; G Eisenhofer; D S Goldstein
Journal:  J Chromatogr B Biomed Appl       Date:  1994-03-04

7.  Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.

Authors:  Jennifer N Rees; Virginia R Florang; Laurie L Eckert; Jonathan A Doorn
Journal:  Chem Res Toxicol       Date:  2009-07       Impact factor: 3.739

Review 8.  Dysautonomia in Parkinson's disease: neurocardiological abnormalities.

Authors:  David S Goldstein
Journal:  Lancet Neurol       Date:  2003-11       Impact factor: 44.182

9.  Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy.

Authors:  David S Goldstein; Courtney Holmes; Oladi Bentho; Takuya Sato; Jeffrey Moak; Yehonatan Sharabi; Richard Imrich; Shielah Conant; Basil A Eldadah
Journal:  Parkinsonism Relat Disord       Date:  2008-03-05       Impact factor: 4.891

10.  Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model.

Authors:  Stephanie Janezic; Sarah Threlfell; Paul D Dodson; Megan J Dowie; Tonya N Taylor; Dawid Potgieter; Laura Parkkinen; Steven L Senior; Sabina Anwar; Brent Ryan; Thierry Deltheil; Polina Kosillo; Milena Cioroch; Katharina Wagner; Olaf Ansorge; David M Bannerman; J Paul Bolam; Peter J Magill; Stephanie J Cragg; Richard Wade-Martins
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 11.205

View more
  17 in total

1.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

2.  3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by N-Acetylcysteine.

Authors:  Yunden Jinsmaa; Yehonatan Sharabi; Patti Sullivan; Risa Isonaka; David S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2018-04-26       Impact factor: 4.030

3.  Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2015-02-25       Impact factor: 5.372

4.  Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.

Authors:  David S Goldstein; Patricia Sullivan; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi; Deborah C Mash
Journal:  Parkinsonism Relat Disord       Date:  2015-03-20       Impact factor: 4.891

5.  Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Patricia Sullivan; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2016-07-20       Impact factor: 4.891

Review 6.  Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky.

Authors:  David S Goldstein; Irwin J Kopin
Journal:  Cell Mol Neurobiol       Date:  2017-05-09       Impact factor: 5.046

Review 7.  The catecholaldehyde hypothesis: where MAO fits in.

Authors:  David S Goldstein
Journal:  J Neural Transm (Vienna)       Date:  2019-12-05       Impact factor: 3.575

Review 8.  Epigenetics in acute kidney injury.

Authors:  Jinhua Tang; Shougang Zhuang
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-07       Impact factor: 2.894

9.  Alpha-Synuclein Deposition Within Sympathetic Noradrenergic Neurons Is Associated With Myocardial Noradrenergic Deficiency in Neurogenic Orthostatic Hypotension.

Authors:  Risa Isonaka; Avi Z Rosenberg; Patti Sullivan; Abraham Corrales; Courtney Holmes; Yehonatan Sharabi; David S Goldstein
Journal:  Hypertension       Date:  2019-04       Impact factor: 10.190

Review 10.  Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.

Authors:  Toshiharu Nagatsu; Ikuko Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.